BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28419548)

  • 21. Prostate cancer biomarker profiles in urinary sediments and exosomes.
    Dijkstra S; Birker IL; Smit FP; Leyten GH; de Reijke TM; van Oort IM; Mulders PF; Jannink SA; Schalken JA
    J Urol; 2014 Apr; 191(4):1132-8. PubMed ID: 24211598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization.
    Eskra JN; Rabizadeh D; Mangold L; Fabian E; Brennen WN; Yeater DB; Pienta KJ; Partin AW; Isaacs WB; Pavlovich CP; Luo J
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):220-232. PubMed ID: 32820256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
    Newcomb LF; Zheng Y; Faino AV; Bianchi-Frias D; Cooperberg MR; Brown MD; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Liss M; Morgan TM; Thompson IM; Wagner AA; Carroll PR; Nelson PS; Lin DW
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):438-445. PubMed ID: 30664734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating RNAs in prostate cancer patients.
    Mugoni V; Ciani Y; Nardella C; Demichelis F
    Cancer Lett; 2022 Jan; 524():57-69. PubMed ID: 34656688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
    Endzeliņš E; Berger A; Melne V; Bajo-Santos C; Soboļevska K; Ābols A; Rodriguez M; Šantare D; Rudņickiha A; Lietuvietis V; Llorente A; Linē A
    BMC Cancer; 2017 Nov; 17(1):730. PubMed ID: 29121858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
    Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
    Laxman B; Morris DS; Yu J; Siddiqui J; Cao J; Mehra R; Lonigro RJ; Tsodikov A; Wei JT; Tomlins SA; Chinnaiyan AM
    Cancer Res; 2008 Feb; 68(3):645-9. PubMed ID: 18245462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Nilsson J; Skog J; Nordstrand A; Baranov V; Mincheva-Nilsson L; Breakefield XO; Widmark A
    Br J Cancer; 2009 May; 100(10):1603-7. PubMed ID: 19401683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
    Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
    Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
    Minciacchi VR; Zijlstra A; Rubin MA; Di Vizio D
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):251-258. PubMed ID: 28374743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
    Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
    Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-Normalized Detection of ANXA3 from Untreated Urine of Prostate Cancer Patients without Digital Rectal Examination.
    Jeun M; Park S; Kim Y; Choi J; Song SH; Jeong IG; Kim CS; Lee KH
    Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28703915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
    Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
    Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
    Pepe P; Aragona F
    Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes.
    Puhka M; Takatalo M; Nordberg ME; Valkonen S; Nandania J; Aatonen M; Yliperttula M; Laitinen S; Velagapudi V; Mirtti T; Kallioniemi O; Rannikko A; Siljander PR; Af Hällström TM
    Theranostics; 2017; 7(16):3824-3841. PubMed ID: 29109780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCA3: from basic molecular science to the clinical lab.
    Day JR; Jost M; Reynolds MA; Groskopf J; Rittenhouse H
    Cancer Lett; 2011 Feb; 301(1):1-6. PubMed ID: 21093148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary biomarkers of prostate cancer.
    Fujita K; Nonomura N
    Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG.
    Warrick JI; Tomlins SA; Carskadon SL; Young AM; Siddiqui J; Wei JT; Chinnaiyan AM; Kunju LP; Palanisamy N
    Mod Pathol; 2014 Apr; 27(4):609-20. PubMed ID: 24072184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.